Coagulopathy and the humoral response against viral proteins in patients at different stages of COVID-19
Monteiro, Fernanda Pereira; Tavares, Victor de Souza; Souza, Rayane da Silva Oliveira; Venâncio, Larissa Paola Rodrigues; Fabres-Klein, Mary Hellen; do Carmo, Rodrigo Feliciano; Klein, Raphael Contelli; Lima, Jonilson Berlink; Araújo-Santos, Théo.
Mem. Inst. Oswaldo Cruz
; 117: e220072, 2022. tab, graf
Artigo
em Inglês
|
LILACS-Express
| ID: biblio-1422143
BACKGROUND Patients with severe coronavirus disease 2019 (COVID-19) often present with coagulopathies and have high titres of circulating antibodies against viral proteins. OBJECTIVES Herein, we evaluated the association between D-dimer and circulating immunoglobulin levels against viral proteins in patients at different clinical stages of COVID-19. METHODS For this, we performed a cross-sectional study involving patients of the first wave of COVID-19 clinically classified as oligosymptomatic (n = 22), severe (n = 30), cured (n = 27) and non-infected (n = 9). Next, we measured in the plasma samples the total and fraction of immunoglobulins against the nucleoprotein (NP) and the receptor-binding domain (RBD) of the spike proteins by enzyme-linked immunosorbent assay (ELISA) assays. FINDINGS Patients with severe disease had a coagulation disorder with high levels of D-dimer as well as circulating IgG against the NP but not the RBD compared to other groups of patients. In addition, high levels of D-dimer and IgG against the NP and RBD were associated with disease severity among the patients in this study. MAIN CONCLUSIONS Our data suggest that IgG against NP and RBD participates in the worsening of COVID-19. Although the humoral response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is partially understood, and more efforts are needed to clarify gaps in the knowledge of this process.
Biblioteca responsável:
BR1.1
Texto completo
Documentos relacionados
